UPDATE: SunTrust Robinson Humphrey Reiterates on Hologic as Deterioration Story Gains Momentum
In a report published Tuesday, SunTrust Robinson Humphrey analyst Amit Hazan reiterated a Reduce rating on Hologic (NASDAQ: HOLX), but lowered the price target from $17.00 to $15.00.
In the report, SunTrust Robinson Humphrey noted, “New guidance for FY14 reflects the reality of deteriorating end markets and only the beginning of significant margin pressure in the years ahead. Declining EBITDA and a two year delay in leverage target guidance are similarly of high concern. Hopes for a return to growth by FY15 look entirely unrealistic to us, and we lower our PT from $17 to $15 in order to reflect what we view as notably greater risk.”
Hologic closed on Monday at $22.90.
Latest Ratings for HOLX
|Jul 2016||Morgan Stanley||Maintains||Equal-weight|
|Jul 2016||Evercore ISI Group||Upgrades||Hold||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.